The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 973-985

  Adachi, Yasushi ^a   Ohashi, Hirokazu ^a   Imsumran, Arisa ^a   Yamamoto, Hiroyuki ^a   Matsunaga, Yasutaka ^a   Taniguchi, Hiroaki ^b   Nosho, Katsuhiko ^a   Suzuki, Hiromu ^a   Sasaki, Yasushi ^a   Arimura, Yoshiaki ^a   Carbone, David P ^c   Imai, Kohzoh ^a,b   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Dominant negative; EAC; ESCC; IGF IR; TKI

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOVIRUS VECTOR; BMS 536924; CISPLATIN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME PHOSPHORYLATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TECHNOLOGY; TISSUE MICROARRAY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOCARCINOMA; ADENOVIRIDAE; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84899124599     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1131-2     Document Type: Article

References (50)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52. (Pubitemid 37485141)
2. Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut. 1994;35:941-5. (Pubitemid 24202724)
3. Baserga R. Oncogenes and the strategy of growth factors. Cell. 1994;79:927-30.
4. Sell C, RubiniM, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993;90:11217-21. (Pubitemid 23354400)
5. Ullrich A, Gray A, Tam AW, Yang-Feng T, TsubokawaM, Collins C, et al. Insulin-like growth factor i receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo J. 1986;5:2503-12.
6. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-89.
7. Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G. Des-(1-3)-igf-i, an insulin-like growth factor analog used to mimic a potential igf-ii autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer. 1992;52:910-7. (Pubitemid 23009508)
8. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (igf)-i and igf-binding protein-3. J Natl Cancer Inst. 1999;91:620-5. (Pubitemid 29194048)
9. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble igf2 receptor rescues apc(min/+) intestinal adenoma progresion induced by igf2 loss of imprinting. Cancer Res. 2006;66:1940-8.
10. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-i and prostate cancer risk: a prospective study. Science. 1998;279:563-6. (Pubitemid 28067285)
11. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor i (igf-1) and type 1 igf receptor (igf1r). Cell. 1993;75:59-72. (Pubitemid 23306021)
12. Vinayek R, Pichney LS, Tantry U, Dutta SK, Resau J, Vengurlekar S. Characterization of insulin-like growth factor i receptors in human esophageal epithelial cells. Am J Physiol. 1994;267:G105-14.
13. Qureshi FG, Tchorzewski MT, Duncan MD, Harmon JW. Egf and igf-i synergistically stimulate proliferation of human esophageal epithelial cells. J Surg Res. 1997;69:354-8. (Pubitemid 27317881)
14. Tchorzewski MT, Qureshi FG, Duncan MD, Duncan KL, Saini N, Harmon JW. Role of insulin-like growth factor-i in esophageal mucosal healing processes. J Lab Clin Med. 1998;132:134-41. (Pubitemid 28378842)
15. Costigan DC, Guyda HJ, Posner BI. Free insulin-like growth factor i (igf-i) and igf-ii in human saliva. J Clin Endocrinol Metab. 1988;66:1014-8.
16. Mori M, Inoue H, Shiraishi T, Mimori K, Shibuta K, Nakashima H, et al. Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer. 1996;68:441-6. (Pubitemid 26414497)
17. Liu YC, Leu CM, Wong FH, Fong WS, Chen SC, Chang C, et al. Autocrine stimulation by insulin-like growth factor i is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci. 2002;9:665-74.
18. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34:803-8. (Pubitemid 37040618)
19. Chen SC, Chou CK, Wong FH, Chang CM, Hu CP. Overexpression of epidermal growth factor and insulin-like growth factor-i receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res. 1991;51:1898-903.
20. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004;64:7711-23. (Pubitemid 39446902)
21. Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, et al. Insulin-like growth factor-i receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007;28:947-56. (Pubitemid 47072177)
22. Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, et al. Igf-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2012;107:196-204.
23. Donohoe CL, Doyle SL, McGarrigle S, CathcartMC, Daly E, O'Grady A, et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg. 2012;99:387-96.
24. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor i receptor. Oncogene. 2003;22:6589-97. (Pubitemid 37372339)
25. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of the human type i insulin-like growth factor receptor antibody a12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005;11:3065-74. (Pubitemid 40525213)
26. Cohen BD, Baker DA, SoderstromC, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody cp-751,871. Clin Cancer Res. 2005;11:2063-73. (Pubitemid 40471873)
27. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of nvp-aew541-a novel, potent, and selective inhibitor of the igf-ir kinase. Cancer Cell. 2004;5:231-9. (Pubitemid 38402115)
28. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221-30. (Pubitemid 38402114)
29. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin- like growth factor i receptor mutant. Proc Natl Acad Sci U S A. 1994;91:2181-5.
30. D'Ambrosio C, Ferber A, ResnicoffM, Baserga R.A soluble insulin-like growth factor i receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 1996;56:4013-20. (Pubitemid 26284753)
31. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 2002;123:1191-204.
32. Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, et al. Genetic blockade of the insulin-like growth factor-i receptor: a promising strategy for human pancreatic cancer. Cancer Res. 2003;63:6432-41. (Pubitemid 37255193)
33. Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-i receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther. 2003;10:57-63. (Pubitemid 36222077)
34. Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, et al. Insulin-like growth factor i receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 2005;54:591-600. (Pubitemid 40559239)
35. Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, et al. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Cancer Sci. 2012;103:252-61.
36. Wang Y, Adachi Y, Imsumran A, Yamamoto H, Piao W, Li H, et al. Targeting for insulin-like growth factor-i receptor with short hairpin RNA for human digestive/gastrointestinal cancers. J Gastroenterol. 2010;45:159-70.
37. Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, et al. Discovery of a (1h-benzoimidazol-2-yl)-1h-pyridin-2-one (bms-536924) inhibitor of insulin-like growth factor i receptor kinase with in vivo antitumor activity. J Med Chem. 2005;48:5639-43. (Pubitemid 41298335)
38. Lee YJ, Imsumran A, Park MY, Kwon SY, Yoon HI, Lee JH, et al. Adenovirus expressing shRNA to igf-1r enhances the chemosensitivity of lung cancer cell lines by blocking igf-1 pathway. Lung Cancer. 2007;55:279-86. (Pubitemid 46343577)
39. Hana V, Murphy LJ. Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line. Endocrinology. 1994;135:2511-6. (Pubitemid 24377410)
40. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996;271:11477-83. (Pubitemid 26155990)
41. Pennisi PA, Barr V, Nunez NP, Stannard B, Le Roith D. Reduced expression of insulin-like growth factor i receptors in mcf-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res. 2002;62:6529-37. (Pubitemid 35364118)
42. Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Gungor C, Effenberger KE, et al. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer. 2010;127:1931-40.
43. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. Microrna-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33-42.
44. Juan HC, Tsai HT, Chang PH, Huang CY, Hu CP, Wong FH. Insulin-like growth factor 1 mediates 5-fluorouracil chemoresistance in esophageal carcinoma cells through increasing survivin stability. Apoptosis. 2011;16:174-83.
45. Zou K, Ju JH, Xie H. Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Acta Pharmacol Sin. 2007;28:721-30. (Pubitemid 46684019)
46. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. Bms-754807, a small molecule inhibitor of insulin-like growth factor-1r/ir. Mol Cancer Ther. 2009;8:3341-9.
47. Bao XH, Takaoka M, Hao HF, Wang ZG, Fukazawa T, Yamatsuji T, et al. Esophageal cancer exhibits resistance to a novel igf-1r inhibitor nvp-aew541 with maintained ras-MAPK activity. Anticancer Res. 2012;32:2827-34.
48. Piao W, Wang Y, Adachi Y, Yamamoto H, Li R, Imsumran A, et al. Insulin-like growth factor-i receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther. 2008;7:1483-93.
49. Ii M, Li H, Adachi Y, Yamamoto H, Ohashi H, Taniguchi H, et al. The efficacy of igf-i receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status. Clin Cancer Res. 2011;17:5048-59.
50. Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-i receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res. 2008;14:4631-9.